Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHOD FOR SELECTION OF CHEMOTHERAPEUTIC AGENTS FOR ADENOCARCINOMA CANCER
Document Type and Number:
WIPO Patent Application WO/2013/019945
Kind Code:
A3
Abstract:
The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.

Inventors:
ISAACSON JEFFREY DEAN (US)
RAPONI MICAL (US)
RANGER-MOORE JAMES (US)
POWELL ERIC L (US)
Application Number:
US2012/049320
Publication Date:
May 08, 2014
Filing Date:
August 02, 2012
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ISAACSON JEFFREY DEAN (US)
RAPONI MICAL (US)
RANGER-MOORE JAMES (US)
POWELL ERIC L (US)
CLOVIS ONCOLOGY INC (US)
VENTANA MED SYST INC (US)
International Classes:
A01N43/04; A61K31/70; C07H19/00
Foreign References:
US20020042391A12002-04-11
US20100016254A12010-01-21
Other References:
FARRELL ET AL.: "Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer", GASTROENTEROLOGY, vol. 136, no. 1, 1 January 2009 (2009-01-01), pages 187 - 195, XP025999654
See also references of EP 2739290A4
Attorney, Agent or Firm:
VENTANA MEDICAL SYSTEMS, INC. et al. (1910 East Innovation Park DriveTucson, AZ, US)
Download PDF: